Drug Trial Radar · NCT00041483
Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD
Last checked: Nov 20, 2026Latest source record: Jul 1, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
530
Actual
Start
Jun 2002
Primary completion
Aug 2005
Study completion Aug 2005
Sponsor
- Lead sponsor
- Alcon ResearchIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate that Anecortave Acetate is as effective after twelve months of treatment as photodynamic therapy (PDT) with Visudyne in patients eligible for initial PDT treatment for wet age-related macular degeneration.
Conditions
- Macular Degeneration
Interventions
Anecortave Acetate 15 mg sterile suspensionDrug
Photodynamic Therapy (PDT)Other
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Patients Maintaining VisionTime frame: Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.